Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study

Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States

(2013) Ronald C.W. Ma et al.   Annals of the New York Academy of Sciences

Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study

(2013) N. Inagaki et al.   DIABETES OBESITY & METABOLISM

Inhibition of Renal Glucose Reabsorption: A Novel Strategy for Achieving Glucose Control in Type 2 Diabetes Mellitus

(2013) Muhammad Abdul-Ghani et al.   Endocrine Practice

Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas

(2013) Yutaka Seino et al.   Journal of Diabetes Investigation

Expression of Na+-d-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences

(2012) Ivan Sabolić et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study

(2012) L.E. Nicolle et al.   CURRENT MEDICAL RESEARCH AND OPINION

Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor

(2012) Paul Nyirjesy et al.   CURRENT MEDICAL RESEARCH AND OPINION

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial

(2012) K. Kaku et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

(2012) K. Stenlöf et al.   DIABETES OBESITY & METABOLISM

Role of sodium-glucose transporters in glucose uptake of the intestine and kidney

(2012) Norio Harada et al.   Journal of Diabetes Investigation

TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity

(2011) K Yamamoto et al.   BRITISH JOURNAL OF PHARMACOLOGY

SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function

(2011) Michael J. Jurczak et al.   DIABETES

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial

(2011) M. A. Nauck et al.   DIABETES CARE

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia

(2011) R. A. DeFronzo et al.   DIABETES OBESITY & METABOLISM

DPP-4 inhibition and islet function

(2011) Bo Ahrén   Journal of Diabetes Investigation

(1S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol (TS-071) is a Potent, Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for Type 2 Diabetes Treatment

(2010) Hiroyuki Kakinuma et al.   JOURNAL OF MEDICINAL CHEMISTRY

Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus

(2010) et al.   Journal of Diabetes Investigation

Familial Renal Glucosuria and SGLT2: From a Mendelian Trait to a Therapeutic Target

(2009) R. Santer et al.   Clinical Journal of the American Society of Nephrology

Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus

(2009) Sunil Nair et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications

(2009) George L. Bakris et al.   KIDNEY INTERNATIONAL